SG52402A1 - Oral administration of immunologically active biomolecules and other therapeutic proteins - Google Patents
Oral administration of immunologically active biomolecules and other therapeutic proteinsInfo
- Publication number
- SG52402A1 SG52402A1 SG1996004016A SG1996004016A SG52402A1 SG 52402 A1 SG52402 A1 SG 52402A1 SG 1996004016 A SG1996004016 A SG 1996004016A SG 1996004016 A SG1996004016 A SG 1996004016A SG 52402 A1 SG52402 A1 SG 52402A1
- Authority
- SG
- Singapore
- Prior art keywords
- protein
- therapeutic protein
- orally
- oral administration
- stabilizing agent
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 230000001225 therapeutic effect Effects 0.000 title abstract 5
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 239000013566 allergen Substances 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 238000004925 denaturation Methods 0.000 abstract 1
- 230000036425 denaturation Effects 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003094 microcapsule Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99493292A | 1992-12-22 | 1992-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG52402A1 true SG52402A1 (en) | 1998-09-28 |
Family
ID=25541237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG1996004016A SG52402A1 (en) | 1992-12-22 | 1993-01-04 | Oral administration of immunologically active biomolecules and other therapeutic proteins |
Country Status (12)
Country | Link |
---|---|
US (1) | US5591433A (fr) |
EP (1) | EP0603992B2 (fr) |
JP (1) | JPH0710771A (fr) |
AT (1) | ATE143803T1 (fr) |
AU (1) | AU664222B2 (fr) |
CA (1) | CA2086631C (fr) |
DE (1) | DE69305313T3 (fr) |
DK (1) | DK0603992T4 (fr) |
ES (1) | ES2095001T5 (fr) |
GR (2) | GR3022090T3 (fr) |
NZ (1) | NZ245618A (fr) |
SG (1) | SG52402A1 (fr) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2109362T3 (es) * | 1991-06-21 | 1998-01-16 | Univ Cincinnati | Unas proteinas administrables oralmente y metodo para hacerlas. |
US6613332B1 (en) | 1991-06-21 | 2003-09-02 | The University Of Cincinnati | Oral administration of therapeutic proteins |
US6083503A (en) * | 1991-08-28 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection |
AU695883B2 (en) * | 1994-04-08 | 1998-08-27 | Brigham And Women's Hospital | Treatment of autoimmune disease using oral tolerization and/or Th2-enhancing cytokines |
US20030202980A1 (en) * | 1995-12-29 | 2003-10-30 | Caplan Michael J. | Methods and reagents for decreasing clinical reaction to allergy |
US5980948A (en) * | 1996-08-16 | 1999-11-09 | Osteotech, Inc. | Polyetherester copolymers as drug delivery matrices |
EP0867188A1 (fr) * | 1996-08-20 | 1998-09-30 | Freund Industrial Co., Ltd. | Microspheres contenant des immunogenes, procede de fabrication et procede permettant d'immuniser des animaux a l'aide de ces microspheres |
EP0943336A1 (fr) * | 1996-09-04 | 1999-09-22 | Dott Research Laboratory | Compositions medicamenteuses contenant des peptides, destinees a l'administration orale |
US8828432B2 (en) | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
US6559158B1 (en) | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
US7879977B2 (en) | 1998-01-31 | 2011-02-01 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
CA2319437C (fr) * | 1998-01-31 | 2009-06-16 | University Of Arkansas | Procedes et reactifs permettant de diminuer les reactions allergiques |
US6328967B1 (en) * | 1998-03-12 | 2001-12-11 | Allergenics, Inc. | Delivery system to modulate immune response |
US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
JP2002507399A (ja) | 1998-03-23 | 2002-03-12 | ゼネラル ミルズ インコーポレイテッド | 可食性製品への成分のカプセル化 |
SE9801288D0 (sv) | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
GB9818591D0 (en) * | 1998-08-27 | 1998-10-21 | Danbiosyst Uk | Pharmaceutical composition |
WO2000054797A2 (fr) | 1999-03-17 | 2000-09-21 | Novartis Ag | Compositions pharmaceutiques |
US6500463B1 (en) | 1999-10-01 | 2002-12-31 | General Mills, Inc. | Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
AU783099B2 (en) * | 2000-01-07 | 2005-09-22 | Rohm Gmbh & Co. Kg | Selective activation of a TH1 or TH2 lymphocyte regulated immune response |
US8246945B2 (en) * | 2000-04-06 | 2012-08-21 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
US20050063994A1 (en) * | 2000-04-06 | 2005-03-24 | Caplan Michael J. | Methods and reagents for decreasing clinical reaction to allergy |
EP1272213B1 (fr) * | 2000-04-06 | 2006-03-08 | SEER Pharmaceuticals, LLC. | Systeme d'administration microbienne |
US6436453B1 (en) | 2000-06-16 | 2002-08-20 | General Mills, Inc. | Production of oil encapsulated minerals and vitamins in a glassy matrix |
US6468568B1 (en) | 2000-06-16 | 2002-10-22 | General Mills, Inc. | Oligosaccharide encapsulated mineral and vitamin ingredients |
US6558718B1 (en) | 2000-06-19 | 2003-05-06 | General Mills, Inc. | Nutrient clusters for food products and methods of preparation |
CA2428114C (fr) | 2000-11-10 | 2013-07-23 | Proteopharma Aps | Analogues d'apolipoproteine |
AU2002314967B2 (en) * | 2001-06-05 | 2007-09-20 | University Of Chicago | Use of methylnaltrexone to treat immune suppression |
BR0117149A (pt) * | 2001-10-15 | 2004-11-23 | R Ehm Gmbh & Co Kg | Uso de um copolìmero para produzir uma forma farmacêutica contendo um peptìdio ou proteìna como agente ativo |
KR100469943B1 (ko) * | 2002-03-20 | 2005-02-02 | 삼성정밀화학 주식회사 | 장용성 코팅제로 사용되는 아크릴 공중합체의 제조 방법 |
US20040043070A1 (en) * | 2002-05-14 | 2004-03-04 | Ayres James W. | Hot melt coating by direct blending and coated substrates |
US7431986B2 (en) | 2002-07-24 | 2008-10-07 | General Mills, Inc. | Encapsulation of sensitive components using pre-emulsification |
PT2368554E (pt) | 2003-04-08 | 2015-02-06 | Progenics Pharm Inc | Formulações farmacêuticas que contêm metilnaltrexona |
US20040259899A1 (en) * | 2003-04-08 | 2004-12-23 | Sanghvi Suketu P. | Combination therapy for constipation |
AU2004229462A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
US20070141071A1 (en) * | 2003-05-14 | 2007-06-21 | Oregon State University | Hot melt coating by direct blending and coated substrates |
WO2005123119A2 (fr) * | 2004-06-10 | 2005-12-29 | Catalyst Biosciences, Inc. | Administration d'endopeptidase neutre afin de traiter les maladies intestinales inflammatoires |
EP1765385A4 (fr) * | 2004-06-16 | 2008-08-27 | Smart Drug Systems Inc | Composition vaccinale à libération prolongée |
EP1845989A1 (fr) * | 2005-01-20 | 2007-10-24 | Progenics Pharmaceuticals, Inc. | Utilisation de methylnaltrexone et de composes apparentes pour traiter un dysfonctionnement gastrointestinal post-operatoire |
CA2600350C (fr) * | 2005-03-07 | 2015-02-10 | The University Of Chicago | Utilisation d'antagonistes opioides pour l'attenuation de la proliferation et de la migration des cellules endotheliales |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8524731B2 (en) * | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
AR057035A1 (es) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
US20080194611A1 (en) * | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
WO2007038926A1 (fr) * | 2005-10-04 | 2007-04-12 | Alk-Abelló A/S | Formulation vaccinale solide |
US7803413B2 (en) | 2005-10-31 | 2010-09-28 | General Mills Ip Holdings Ii, Llc. | Encapsulation of readily oxidizable components |
WO2007112747A1 (fr) * | 2006-03-31 | 2007-10-11 | Curalogic A/S | Combinaisons d'immunogenes |
TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
CA2865389A1 (fr) * | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Formes cristallines et leurs utilisations |
MX2009010515A (es) * | 2007-03-29 | 2009-10-19 | Wyeth Corp | Antagonistas del receptor opioide periferico y usos de los mismos. |
ES2570374T3 (es) * | 2007-03-29 | 2016-05-18 | Progenics Pharm Inc | Antagonistas del receptor opioide periférico y usos de los mismos |
CN101959892B (zh) | 2008-02-06 | 2014-01-08 | 普罗热尼奇制药公司 | (r),(r)-2,2’-二-甲基纳曲酮的制备和用途 |
EP2278966B1 (fr) | 2008-03-21 | 2019-10-09 | The University of Chicago | Traitement avec des antagonistes des opioïdes et des inhibiteurs mtor |
CA2726193C (fr) | 2008-06-03 | 2018-11-27 | University Of Rochester | Procedes de traitement de maladie intestinale inflammatoire et gestion des symptomes de celle-ci |
ES2620373T3 (es) | 2008-07-01 | 2017-06-28 | University Of Chicago | Partículas que contienen un antagonista del receptor de opioides periférico |
JP2010077057A (ja) * | 2008-09-25 | 2010-04-08 | Kagoshima Univ | 抗食物アレルギーワクチン |
CA2676881C (fr) | 2008-09-30 | 2017-04-25 | Wyeth | Antagonistes de recepteurs opioides peripheriques, et leurs utilisations |
JP5931449B2 (ja) * | 2012-01-11 | 2016-06-08 | 日東電工株式会社 | 医薬組成物及びその製造方法 |
US10940170B2 (en) | 2014-07-07 | 2021-03-09 | University Of Massachusetts | Anthelmintic probiotic compositions and methods |
CN107249327A (zh) | 2014-10-17 | 2017-10-13 | 萨利克斯药品公司 | 使用甲基纳曲酮减缓肿瘤进展 |
WO2017123946A1 (fr) | 2016-01-15 | 2017-07-20 | University Of Massachussetts | Compositions anthelmintiques et méthodes associées |
EP3630150A4 (fr) | 2017-05-23 | 2021-04-28 | University of Massachusetts | Compositions anthelminthiques purifiées et méthodes associées |
CA3120619A1 (fr) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methodes et dispositifs pour traiter une maladie a l'aide d'agents biotherapeutiques |
WO2020257017A1 (fr) | 2019-06-18 | 2020-12-24 | Progenity, Inc. | Dispositif ingérable doté d'un composant capable de résider dans le tractus gastro-intestinal |
US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE621398A (fr) * | 1900-01-01 | |||
US3143473A (en) * | 1961-08-16 | 1964-08-04 | Behringwerke Ag | Stable, solid, oral live antipoliomyelitis vaccine compositions and process for preparing them |
US3458621A (en) * | 1966-08-31 | 1969-07-29 | American Home Prod | Tablet dosage-form for the immunization of the intestinal tract with live virus preparations |
US3909444A (en) * | 1971-08-05 | 1975-09-30 | Ncr Co | Microcapsule |
US3823228A (en) * | 1971-09-29 | 1974-07-09 | Univ Illinois | Tge virus vaccine |
US3860490A (en) * | 1972-02-11 | 1975-01-14 | Nat Patent Dev Corp | Process of subjecting a microorganism susceptible material to a microorganism |
US3767790A (en) * | 1972-02-11 | 1973-10-23 | Nat Patent Dev Corp | Microorganisms |
US4016254A (en) * | 1972-05-19 | 1977-04-05 | Beecham Group Limited | Pharmaceutical formulations |
JPS517116A (en) * | 1974-06-11 | 1976-01-21 | Shinetsu Chemical Co | Choyoseihifukuyakuzaino seizohoho |
US4269764A (en) * | 1979-08-02 | 1981-05-26 | Roy Patterson | Preparation for treatment of allergic patients sensitive to ragweed pollen |
US4469677A (en) * | 1980-02-19 | 1984-09-04 | Michael J Gabriel | Polypeptide active immunosuppressant fraction |
JPS5855125B2 (ja) * | 1980-03-10 | 1983-12-08 | 信越化学工業株式会社 | 固形薬剤用腸溶性コ−テイング剤組成物 |
JPS56142211A (en) * | 1980-04-09 | 1981-11-06 | Riken Vitamin Co Ltd | Production of enteric preparation |
US4348384A (en) * | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
US4507276A (en) * | 1982-08-20 | 1985-03-26 | Bristol-Myers Company | Analgesic capsule |
SE8303401D0 (sv) * | 1983-06-15 | 1983-06-15 | Pharmacia Ab | Beredning och dess anvendning |
GB8321178D0 (en) * | 1983-08-05 | 1983-09-07 | Beecham Group Plc | Compositions |
US4704295A (en) * | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
US4794000A (en) * | 1987-01-08 | 1988-12-27 | Synthetic Blood Corporation | Coacervate-based oral delivery system for medically useful compositions |
DE3431861A1 (de) * | 1984-08-30 | 1986-03-13 | Troponwerke GmbH & Co KG, 5000 Köln | Pellet-zubereitung |
ZA858044B (en) * | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
EP0192321A3 (fr) * | 1985-01-19 | 1987-09-02 | Beecham Group Plc | Compositions pharmaceutiques avec enrobage entérique contenant des allergènes |
CH663900A5 (de) * | 1985-05-06 | 1988-01-29 | Cernitin Sa | Pharmazeutisches praeparat zur prophylaktischen behandlung von allergien und verfahren zur herstellung dieses praeparates. |
IL78775A (en) * | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
GB8519310D0 (en) * | 1985-07-31 | 1985-09-04 | Zyma Sa | Granular active substances |
US4820627A (en) * | 1986-03-24 | 1989-04-11 | Em Diagnostic Systems, Inc. | Method of preparing particles suitable for tabletting into diagnostic reagents |
JPH0759496B2 (ja) * | 1986-03-25 | 1995-06-28 | ロ−ト製薬株式会社 | 歯周病治療剤 |
US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
FR2609895B1 (fr) * | 1987-01-28 | 1991-06-28 | Bruttmann Georges | Nouvelles formes galeniques d'allergenes pour administration par voie per- et sub-linguale |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
JPS6417A (en) * | 1987-02-20 | 1989-01-05 | Shikoku Chem Corp | Chemotherapeutic agent composition |
US4874613A (en) * | 1987-03-06 | 1989-10-17 | Baker Cummins Pharmaceuticals, Inc. | Taste concealing pharmaceutical dosage unit |
US4946945A (en) * | 1987-06-23 | 1990-08-07 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
US5116612A (en) * | 1987-06-23 | 1992-05-26 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
US5049390A (en) * | 1987-09-02 | 1991-09-17 | Allergy Immuno Technologies, Inc. | Liposome containing immunotherapy agents for treating IgE mediated allergies |
IL87710A (en) * | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
US5236713A (en) * | 1987-10-21 | 1993-08-17 | Teikoku Seiyaku Kabushiki Kaisha | Preparation for intermittently releasing active agent applicable to oral cavity |
GB8826116D0 (en) * | 1988-11-08 | 1988-12-14 | Danbiosyst Ltd | Adhesive drug delivery composition |
DE69001898T2 (de) * | 1989-03-17 | 1993-09-23 | Pitman Moore Inc | Kontrollierte, verzoegerte wirkstofffreisetzung von makromolekularen proteinen. |
US5047258A (en) * | 1989-07-14 | 1991-09-10 | Sterling Drug Inc. | Aqueous spray-coating process |
US5032405A (en) * | 1989-09-27 | 1991-07-16 | Warner-Lambert Company | Oral pharmaceutical composition for acid sensitive proteinaceous agents |
AU7908791A (en) * | 1990-05-08 | 1991-11-27 | Liposome Technology, Inc. | Direct spray-dried drug/lipid powder composition |
US5149543A (en) * | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
CA2092905C (fr) * | 1990-10-15 | 2002-01-08 | Howard L. Weiner | Traitement de maladies auto-immunes par l'administration orale d'autoantigenes |
JPH04230625A (ja) * | 1990-12-27 | 1992-08-19 | Standard Chem & Pharmaceut Corp Ltd | 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法 |
ES2109362T3 (es) † | 1991-06-21 | 1998-01-16 | Univ Cincinnati | Unas proteinas administrables oralmente y metodo para hacerlas. |
US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
-
1993
- 1993-01-04 DK DK93300005T patent/DK0603992T4/da active
- 1993-01-04 EP EP19930300005 patent/EP0603992B2/fr not_active Expired - Lifetime
- 1993-01-04 CA CA 2086631 patent/CA2086631C/fr not_active Expired - Lifetime
- 1993-01-04 SG SG1996004016A patent/SG52402A1/en unknown
- 1993-01-04 AT AT93300005T patent/ATE143803T1/de not_active IP Right Cessation
- 1993-01-04 ES ES93300005T patent/ES2095001T5/es not_active Expired - Lifetime
- 1993-01-04 DE DE69305313T patent/DE69305313T3/de not_active Expired - Lifetime
- 1993-01-05 AU AU31045/93A patent/AU664222B2/en not_active Ceased
- 1993-01-06 JP JP3107493A patent/JPH0710771A/ja active Pending
- 1993-01-06 NZ NZ245618A patent/NZ245618A/en not_active IP Right Cessation
-
1995
- 1995-01-20 US US08/405,604 patent/US5591433A/en not_active Expired - Lifetime
-
1996
- 1996-12-18 GR GR960403537T patent/GR3022090T3/el unknown
-
2001
- 2001-02-22 GR GR20010400286T patent/GR3035452T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0603992A1 (fr) | 1994-06-29 |
ES2095001T3 (es) | 1997-02-01 |
DK0603992T3 (da) | 1997-03-24 |
NZ245618A (en) | 1994-10-26 |
ATE143803T1 (de) | 1996-10-15 |
DK0603992T4 (da) | 2001-03-05 |
EP0603992B2 (fr) | 2000-12-06 |
EP0603992B1 (fr) | 1996-10-09 |
JPH0710771A (ja) | 1995-01-13 |
ES2095001T5 (es) | 2001-03-16 |
CA2086631A1 (fr) | 1994-06-23 |
DE69305313D1 (de) | 1996-11-14 |
DE69305313T3 (de) | 2001-06-21 |
AU3104593A (en) | 1994-07-07 |
US5591433A (en) | 1997-01-07 |
AU664222B2 (en) | 1995-11-09 |
DE69305313T2 (de) | 1997-02-20 |
CA2086631C (fr) | 1998-10-06 |
GR3035452T3 (en) | 2001-05-31 |
GR3022090T3 (en) | 1997-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG52402A1 (en) | Oral administration of immunologically active biomolecules and other therapeutic proteins | |
EP0590060A4 (en) | Orally administrable therapeutic proteins and method of making | |
NO964864L (no) | Orale, flytende alendronatpreparater | |
RU97106769A (ru) | Высушенные распылением микрочастицы как терапевтические носители | |
RU93004764A (ru) | Амиды сульфамидо- и сульфамидокарбонилпиридин-2-карбоновых кислот, их пиридин-n-оксиды, способ их получения и их применение в качестве лекарственных препаратов | |
JP2002161050A (ja) | 生活の質を改善する新規医薬組成物ならびに新規食品の製法および用途 | |
MX9304346A (es) | Composicion de vacuna oral para especies rumiantes y metodo para su produccion. | |
WO2001022934A3 (fr) | Apport de faibles doses de traitement par ingestion | |
IS3644A7 (is) | Aðferð til að framleiða lyfjablöndu á formi smápilla til að meðhöndla þarmabólgur | |
WO2002064148A3 (fr) | Preparation contenant un mucopolysaccharide et son procede de production | |
HK1003979A1 (en) | Chemically modified allergens and process for the preparation thereof | |
ES2044848T3 (es) | Empleo de extractos de petasita para preparar un medicamento para el tratamiento de enfermedades gastrointestinales. | |
JPH01128932A (ja) | ウズラの卵のガレン製剤の製造方法 | |
RU1808324C (ru) | Способ профилактики и лечени казеинобезоарной болезни новорожденных гн т | |
RU94019564A (ru) | Способ лечения желудочно-кишечных заболеваний | |
RU2099061C1 (ru) | Способ лечения нейродермита | |
WO1999049882A3 (fr) | Facteur de croissance endotheliale vasculaire (vegf) et facteur de croissance endotheliale vasculaire c (vegf-c) utilises comme supplements | |
Bisno et al. | Treatment of infective endocarditis due to viridans streptococci, This statement was prepared by the ad hoc subcommittee on Treatment of Bacterial endocarditis of the American Heart Association Council on Cardiovascular Disease in the Young | |
RU2000104571A (ru) | Способ коррекции иммунной недостаточности при желудочно-кишечных заболеваниях поросят | |
RU93056259A (ru) | Средство для лечения диспепсии телят | |
SE9003096D0 (sv) | Device for administering a physiologically active substance to the gastro-intestinal tract | |
RU95105357A (ru) | Способ лечения пищевой аллергии | |
Gupta et al. | Preparation and characterization of detoxified lipopolysaccharide-cholera toxin conjugate vaccine for cholera | |
KR950013512A (ko) | 게라니올을 주제로한 질병치료용 약제의 제조 방법 | |
RU98119939A (ru) | Лекарственное средство и способ стимуляции иммунитета у больных острыми воспалительными заболеваниями придатков матки |